Citi analyst David Lebowitz maintains $PTC Therapeutics (PTCT.US)$ with a sell rating, and adjusts the target price from $26 to $32.
According to TipRanks data, the analyst has a success rate of 52.6% and a total average return of 2.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $PTC Therapeutics (PTCT.US)$'s main analysts recently are as follows:
The update to the company's model reflects the Novartis collaboration, which significantly enhances the liquidity position of the company, now estimated at $2 billion. The collaboration concerning PTC518 is highlighted as bringing significant pharmaceutical industry support and substantial immediate financial benefits.
PTC Therapeutics recently announced a comprehensive global licensing and collaboration agreement with Novartis for its Huntington's Disease program, PTC518. This agreement provides PTC Therapeutics with a significant immediate cash boost and the potential for future earnings through various development, regulatory, and sales milestones. Analysts view this deal favorably, noting that it not only offers PTC substantial financial benefits but also maintains advantageous economic terms and presents a significant opportunity for success. Furthermore, PTC Therapeutics is regarded as a promising player in the rare disease sector, anticipated to present several key catalysts over the forthcoming year.
It is noted with optimism that the recent exclusive strategic license agreement for the global development of PTC518 in Huntington's disease may reduce the immediate financial requirements for the company. Furthermore, as the company continues to seek regulatory agreement on an accelerated approval pathway following an encouraging phase 2 update in June, there remains anticipation around forthcoming elaborations on future development strategies which are perceived as still requiring risk mitigation.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
花旗分析师David Lebowitz维持$PTC Therapeutics (PTCT.US)$卖出评级，并将目标价从26美元上调至32美元。
根据TipRanks数据显示，该分析师近一年总胜率为52.6%，总平均回报率为2.7%。
此外，综合报道，$PTC Therapeutics (PTCT.US)$近期主要分析师观点如下：
公司模型的更新反映了与诺华的合作，这显著增强了公司的流动性状况，目前估计为20亿。关于PTC518的合作被强调为带来了显著的药品行业支持和可观的即时财务利益。
ptc therapeutics最近宣布与诺华就其亨廷顿氏病项目PTC518达成了一项全面的全球许可与合作协议。该协议为ptc therapeutics提供了显著的即时现金支持，并通过各种开发、监管和销售里程碑的潜在收益来实现未来的收益。分析师对这笔交易持积极态度，指出它不仅为ptc带来了可观的财务利益，还保持了有利的经济条款并提供了成功的重大机会。此外，ptc therapeutics被视为在罕见疾病板块中颇具潜力的参与者，预计将在未来一年中推出多个关键催化剂。
乐观地指出，最近针对PTC518在亨廷顿氏病全球开发的独占战略许可协议可能会减少公司的即时财务需求。此外，随着公司继续寻求就加速批准路径达成监管协议，继6月的积极第二阶段更新后，仍对未来发展战略的进一步详细说明抱有期待，这些战略被认为仍需进行风险缓解。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
